Jump Crypto Sets Out to Build New Validator Client for the Solana Blockchain to Increase the Throughput and Reliability of the Network
14.9.2022 21:59:00 EEST | Business Wire | Press release
Jump Crypto, an organization that develops critical infrastructure needed to catalyze the growth of the crypto ecosystem, and the Solana Foundation, a non-profit organization dedicated to the decentralization, advancement, and security of the Solana network, a high performance blockchain, today announced an ambitious undertaking to boost the throughput and reliability of the Solana network by developing a new open source validator client for the network using the C++ programming language.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220816005628/en/
Validators are the heart of any decentralized proof of stake blockchain, and this initiative to develop a second independent client for the Solana blockchain represents an important step in the network’s continued decentralization. Jump Crypto will propose significant upgrades to Solana’s open-source core software along with building a second and new validator client, separate from the one built by Solana Labs.
“After a close evaluation of potential contributors that could build the kind of technological infrastructure needed to undertake this complex of a project, I believe Jump Crypto is an excellent choice to lead this effort,” said Dan Albert, Executive Director of the Solana Foundation. “Jump has unparalleled experience with over 20 years of scaling networks and building highly performant software systems. Their contributions to the Solana network will improve mission-critical systems, helping the network scale to billions of users.”
“While this is a wildly ambitious project, Jump has always been focused on building the guardrails and infrastructure of blockchain technology,” said Kanav Kariya, President of Jump Crypto. “There is nothing more important right now than solving the world's most complex networking issues, and we are thrilled that Solana Foundation has entrusted us to help revolutionize this technology to make the fastest blockchain even faster and more reliable.”
“The Solana network has seen exponential growth over the last two years, which shows no signs of slowing down,” added Anatoly Yakovenko, Co-Founder of Solana. “By adding more core contributors like Jump Crypto, the network can maintain its status as the best place to build in web3, while scaling to billions of users. I’m excited for Jump’s engineers to bring a new perspective to the network and help improve network resiliency and efficiency.”
The process of building a new validator client will be overseen by Kevin Bowers, Chief Science Officer at Jump Trading, who leads an established team of scientists and engineers that has developed complex algorithms, software, hardware, and networks for one of the largest low latency trading systems in the world. Dr. Bowers joined Jump Trading in 2010 as a systems architect after six years as a scientist at D.E. Shaw Research, where he helped create multiple award-winning numerical methods, software, hardware, and networks for some of the world’s fastest and longest biochemical molecular dynamics simulations. His research at Los Alamos and, separately, UC-Berkeley on plasma simulation received similar recognition. Codes he architected have been described and used in hundreds of highly cited scientific papers, featured in the general media and museums, successfully open-sourced and commercialized and remain anchor applications for the world's largest supercomputers.
“Through Jump’s decades of work in solving some of the most complex networking challenges across traditional financial markets, we have seen first-hand the impact that improving a network’s speed and efficiency can have on an entire financial system,” said Kevin Bowers. “Now, given the relatively slow speeds and unreliability of blockchain networks, an incredible opportunity exists to transform the functionality and efficacy of these networks. We are excited to apply our proven technologies to encourage widespread adoption, creating endless possibilities and driving real change in the world.”
To learn more, visit https://www.firedancer.io
About Jump Crypto
Jump Crypto is committed to building and standing up critical infrastructure needed to catalyze the growth of the crypto ecosystem. They are builders, partners, and traders who take a long-term view of crypto's prospects and operate to unlock the full potential of open, community-driven networks. Since its inception as a skunkworks intern project in late 2015, Jump Crypto has grown into a dynamic and seasoned team of high performing players across a range of functions. Today, Jump Crypto plays an important role in the development of some of the largest and most innovative crypto communities. Jump Crypto is the crypto division of Jump Trading Group, a research-driven quantitative trading firm that's one of the largest traders by volume across traditional asset classes. To learn more, please visit https://jumpcrypto.com
About Solana Foundation
The Solana Foundation supports the decentralization, adoption and security of the Solana ecosystem, as a non-profit foundation based in Zug, Switzerland. For more information, please visit https://solana.org/.
About Solana
Solana is a blockchain built for mass adoption. It’s a high performance network that is utilized for a range of use cases, including finance, NFTs, payments, and gaming. Solana operates as a single global state machine, and is open, interoperable and decentralized. For more information, please visit https://solana.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220816005628/en/
Contact information
Media
Jump Crypto
Carissa Felger/Graham Kahr
Gasthalter & Co.
(212) 257-4170
Solana
press@solana.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
